Logo

RDGT

Ridgetech Inc.

RDGT

Ridgetech Inc. • NASDAQ
$4.07 ▲ 5.99% (+0.23)
Market Cap $23.83 M
52w High $5.07
52w Low $0.72
Dividend Yield 0%
P/E -15.65
Volume 22.29K
Outstanding Shares 5.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $71.16M ▼ $16.82M ▼ $-2.278M ▲ -3.201% ▲ $-423.58 ▼ $-1.722M ▲
Q4-2024 $75.966M ▼ $18.966M ▲ $-3.31M ▼ -4.357% ▼ $-1.96 ▼ $-3.34M ▼
Q2-2024 $78.574M ▲ $15.678M ▼ $-924K ▲ -1.176% ▲ $-0.78 ▲ $576.948K ▲
Q4-2023 $76.09M ▲ $37.04M ▲ $-20.544M ▼ -26.999% ▼ $-25.9 ▼ $-19.613M ▼
Q2-2023 $72.722M $18.165M $-594.782K -0.818% $-2.62 $-614.15K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $12.78M ▼ $64.485M ▼ $34.848M ▼ $29.636M ▲
Q2-2025 $18.001M $94.191M $74.07M $21.468M
Q1-2025 $18.001M ▼ $94.191M ▼ $74.07M ▼ $21.468M ▲
Q4-2024 $20.15M ▲ $95.057M ▲ $80.764M ▲ $15.64M ▼
Q2-2024 $18.65M $94.768M $77.23M $18.885M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.278M ▲ $-9.954M ▼ $-430K ▲ $7.828M ▲ $31.093M ▲ $-10.384M ▼
Q4-2024 $-3.31M ▼ $-3.878M ▼ $-714K ▲ $7.676M ▲ $0 $-4.558M ▼
Q2-2024 $-924K ▲ $722.702K ▲ $-1.326M ▼ $327.924K ▼ $0 $546.642K ▲
Q4-2023 $-20.544M ▼ $-4.341M ▼ $-232.676K ▼ $5.35M ▲ $0 $-4.557M ▼
Q2-2023 $-594.782K $1.058M $-83.422K $-2.984M $0 $974.32K

Five-Year Company Overview

Income Statement

Income Statement Ridgetech’s income statement shows a business that is still very small in scale, with revenue that has been broadly flat over the past several years rather than clearly growing. Profitability has been inconsistent: earlier years show modest losses or break-even results, while the most recent year edges back into a small profit. That improvement is encouraging but still fragile, as it seems more like an early sign of a turnaround than a firmly established trend. Margins look thin, which is typical for distribution businesses but still a point of risk here. The company’s past swings in reported earnings per share are heavily influenced by share restructurings, so the headline per‑share figures can look dramatic without reflecting a similarly dramatic shift in the underlying business. Overall, this is a company in transition, with earnings that have not yet settled into a stable pattern.

Balance Sheet

Balance Sheet The balance sheet appears lean, with a relatively small base of assets, modest cash, and a limited amount of equity. Debt has come down from prior years but is still present, which means there is some financial leverage but not an overwhelming amount. The rise in equity in the most recent year suggests some rebuilding of the capital base, but the overall financial cushion is still not large. In practical terms, Ridgetech does not look overburdened by debt, yet it also does not have a deep buffer to absorb major shocks or fund aggressive growth purely from its own resources. The balance sheet is workable but tight, which increases the importance of careful execution and consistent cash generation going forward.

Cash Flow

Cash Flow Cash flow from operations has hovered around break-even, with occasional small outflows. Free cash flow has followed the same pattern, and capital spending has been very light. This indicates a business that is not burning heavy cash on investments, but also not yet generating strong, surplus cash from its day‑to‑day operations. The upside is that Ridgetech is not heavily tying up funds in big projects, which reduces capital risk. The downside is that limited operating cash flow gives the company relatively little self‑funded firepower for expansion, technology build‑out, or buffering against downturns. Sustained, positive operating cash flow will be a key marker of whether the new wholesale‑focused model is gaining traction.

Competitive Edge

Competitive Edge Ridgetech is repositioning itself from a retail pharmacy operator to a wholesale‑focused pharmaceutical and healthcare distributor, mainly in China. Its competitive angle lies in a hybrid online‑offline network, strengthened by the acquisition of Allright, and a presence on large e‑commerce platforms like Tmall and JD. This gives it access to a wide range of customers, from hospitals and pharmacies to online consumers. At the same time, the company operates in a highly crowded and regulated market, going up against large state‑linked distributors and many regional players that may have deeper relationships and greater scale. Ridgetech’s focus on Traditional Chinese Medicine and herb farming provides a niche, but not an obvious, unassailable moat. The company’s competitive position is evolving and depends heavily on how well it can integrate acquisitions, grow volume, manage pricing, and carve out a defensible role in the supply chain.

Innovation and R&D

Innovation and R&D Ridgetech’s innovation story is more about business model and digital enablement than about classic laboratory R&D. The company is leaning into online wholesale distribution, data and information systems, and a more integrated supply‑chain approach. Past references to “smart drugstores” suggest experimentation with technology‑enhanced retail experiences, though recent details are sparse. Currently, Ridgetech relies heavily on third‑party platforms for its online presence rather than on clearly differentiated proprietary technology. The newly acquired online platform is still early in its contribution, but its initial margins hint at potential benefits from scaling a more digital, wholesale‑centric model. Looking ahead, meaningful investments in proprietary e‑commerce and logistics systems, better analytics, and deep integration with manufacturers and healthcare institutions would be the main levers to turn today’s strategy into a more durable innovation edge.

Summary

Ridgetech is a healthcare distributor in the middle of a strategic pivot, moving away from its legacy retail pharmacy roots toward a wholesale‑driven, online‑enabled distribution model. The financials show a company with flat revenue over several years, thin margins, and a recent but still modest return to profitability. The balance sheet and cash flows are adequate but not abundant, leaving limited room for major missteps and placing a premium on disciplined execution. On the strategic side, the company’s hybrid online and offline network, presence on major e‑commerce platforms, and focus on both conventional pharmaceuticals and Traditional Chinese Medicine give it a differentiated profile, but not yet a clearly entrenched moat. The main opportunities lie in scaling the wholesale business, deepening digital capabilities, and building stronger partnerships across the healthcare ecosystem. The main risks stem from intense competition, regulatory complexity in China, integration challenges, and the company’s relatively tight financial resources during this transition phase.